Anti-plasma kallikrein antibodies
AssigneeTakeda Pharmaceutical Company Limited
InventorsAndrew Nixon, Jon A. Kenniston, Stephen R. Comeau
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
Claims10
A method for inhibiting plasma kallikrein (pKal) activity, comprising administering to a subject an effective amount of an antibody that binds pKal, wherein the antibody comprises:
- a heavy chain variable region that comprises a complementarity determining region 1 (HC CDR1) comprising the sequence HYIMM (SEQ ID NO:
- 62), a complementarity determining region 2 (HC CDR2) comprising the sequence GIYSSGGITVYADSVKG (SEQ ID NO:
- 63), and a complementarity determining region 3 (HC CDR3) comprising the sequence (HC CDR3) comprising the sequence
- (i)
- (SEQ ID NO:
- 28)
- RRIGIPRRDAFDI;
- (ii)
- (SEQ ID NO:
- 29)
- RRIGIPRRDEFDI;
- (iii)
- (SEQ ID NO:
- 30)
- RRTGAPRRDAFDI;
- (iv)
- (SEQ ID NO:
- 31)
- RRTGSPRRDAFDI;
- (v)
- (SEQ ID NO:
- 32)
- RRTGLPRRDAFDI;
- or
- (vi)
- (SEQ ID NO:
- 33)
- RRTGIPRRDEFDI;
- and
- a light chain (LC) variable region that comprises a complementarity determining region 1 (LC CDR1) comprising the sequence RASQSISSWLA (SEQ ID NO:
- 59), a complementarity determining region 2 (LC CDR2) comprising the sequence KASTLES (SEQ ID NO:
- 60), and a complementarity determining region 3 (LC CDR3) comprising the sequence QQYNTYWT (SEQ ID NO:
- 61).
Dependencies are inferred from the claim text.